Targeted ADCs For Advanced Lung Cancer

Written by The Life Science Feed Editorial Team · Published 29 May 2026 · Edited by James Carter

EDITORIAL & AI STANDARDS

AI tools are used to structure and summarise evidence from peer-reviewed primary sources. Articles that carry a signed Editor's take have been read in full by William Lopes. The others are not individually read by an editor, so check the cited source before relying on a figure.

REFERENCES

1. 1. Goto K et al. DESTINY-Lung01: trastuzumab deruxtecan in HER2-mutant NSCLC. J Clin Oncol. 2023;41:4757-4767
2. 2. Smit EF et al. DESTINY-Lung02: trastuzumab deruxtecan in HER2-mutant NSCLC. Nat Med. 2023;29:2932-2940
3. 3. Janne PA et al. TROPION-Lung01: datopotamab deruxtecan vs docetaxel in pre-treated NSCLC. J Clin Oncol. 2024 doi:10.1200/adn.24.201890
4. 4. Manegold C. Bevacizumab for NSCLC. Expert Rev Anticancer Ther. 2008;8:689-699
5. 5. Nakagawa K et al. RELAY: erlotinib plus ramucirumab in EGFR-mutant NSCLC. Lancet Oncol. 2019;20:1655-1669

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com